Previous 10 | Next 10 |
MORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has been awarded the Vaccine Industry Excellence Award for Best Contract Research Organization (CRO). Presente...
MORRISVILLE, N.C., April 04, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Jeanine O’Kane as President of Syneos Health Communications — a portfolio of agencies spanning advertis...
2023-03-30 06:51:04 ET Contract research organization Syneos Health ( NASDAQ: SYNH ) announced Thursday the appointment of Stanford (Ben) Rudnick as the company's Interim Chief Financial Officer and principal financial officer, effective tomorrow. Rudnick served as Syneos'...
MORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical Affairs Digital Amplifier, a program designed to drive smarter and more effective scientific ex...
MORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with KX, maker of kdb, the world’s fastest time series database and analytics engine. T...
2023-03-20 16:34:42 ET Syneos Health ( NASDAQ: SYNH ) will leverage Microsoft's ( NASDAQ: MSFT ) Open AI platform to speed up clinical development and improve commercial performance for biopharma customers. Syneos ( SYNH ) has already developed an advanced anal...
MORRISVILLE, N.C., March 20, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic multi-year agreement with Microsoft. Utilizing Microsoft Azure services, Syneos Health has developed an ad...
Syneos Health ( NASDAQ: SYNH ) may be worth toward the midpoint of a range of $40-$53 a share, according to a Barclays analyst. The analysis comes after after a Monday report that the contract research organization has started a new effort to sell itself, sending Syneos shares up 6.4%...
MORRISVILLE, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of a Decentralized Clinical Trial (DCT) Site Network to drive appropriate DCT adoption and enable high qual...
Syneos Health ( NASDAQ: SYNH ) rose 7.5% on a report that the contract research organization has started a new effort to sell itself. Syneos ( SYNH ) hired Bank of America and Centerview as its financial advisors to explore a new set of talks with potential buyers, including i...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...